• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高血压的固定复方疗法:聚焦缬沙坦/氢氯噻嗪复方制剂(代文/氢氯噻嗪)

Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT).

作者信息

Chrysant Steven G

机构信息

University of Oklahoma, Oklahoma Cardiovascular and Hypertension Center, 5850 W Wilshire Blvd, Oklahoma City, OK 73132-4904, USA.

出版信息

Expert Rev Cardiovasc Ther. 2003 Sep;1(3):335-43. doi: 10.1586/14779072.1.3.335.

DOI:10.1586/14779072.1.3.335
PMID:15030262
Abstract

Hypertension is a major risk factor for cardiovascular morbidity and mortality. Monotherapy of hypertension is often ineffective, since it controls approximately 50% of the blood pressure of hypertensive patients. For lowering blood pressure to less than 140/90 mmHg (or <130/80 mmHg among people with diabetes or chronic renal disease) according to JNC-7 guidelines, combination therapy of two or more drugs is often necessary. The combination of a diuretic with an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) is effective and provides the additional benefit of blocking the effects of angiotensin II, which is responsible for cardiovascular remodeling and its complications. ARBs may have an advantage over the ACEIs because they block the action of all angiotensin II directly, whereas ACEIs are ineffective in blocking angiotensin II generated by nonclassical ACE pathways. Valsartan (Diovan, Novartis) is one of the seven currently approved ARBs in the USA for the treatment of hypertension, and it has been shown to be very effective in controlling blood pressure given once-daily in doses of 80-160 or 320 mg. Its fixed combination with hydrochlorothiazide (HCT) is even more effective in controlling blood pressure in 70% of the cases. The most commonly used combinations are valsartan/HCT (Diovan/HCT), 80/12.5 and 160/12.5 mg given once-daily.

摘要

高血压是心血管疾病发病和死亡的主要危险因素。高血压的单一疗法往往无效,因为它只能控制约50%高血压患者的血压。根据美国国立综合癌症网络(JNC)-7指南,为了将血压降至低于140/90 mmHg(糖尿病或慢性肾病患者低于130/80 mmHg),通常需要两种或更多药物的联合治疗。利尿剂与血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体阻滞剂(ARB)联合有效,且能额外阻断血管紧张素II的作用,血管紧张素II会导致心血管重塑及其并发症。ARB可能比ACEI更具优势,因为它们能直接阻断所有血管紧张素II的作用,而ACEI对非经典ACE途径产生的血管紧张素II无效。缬沙坦(代文,诺华公司)是美国目前批准用于治疗高血压的七种ARB之一,已证明每日一次服用80 - 160或320 mg剂量时,在控制血压方面非常有效。它与氢氯噻嗪(HCT)的固定复方在70%的病例中控制血压效果更佳。最常用的复方制剂是缬沙坦/HCT(代文/HCT),每日一次服用80/12.5和160/12.5 mg。

相似文献

1
Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT).高血压的固定复方疗法:聚焦缬沙坦/氢氯噻嗪复方制剂(代文/氢氯噻嗪)
Expert Rev Cardiovasc Ther. 2003 Sep;1(3):335-43. doi: 10.1586/14779072.1.3.335.
2
[First fixed combination of sartan and high-dosage diuretic. A strong duo against high blood pressure].[首个沙坦类与高剂量利尿剂的固定复方制剂。对抗高血压的强力组合]
MMW Fortschr Med. 2004 Apr 1;146(14):45.
3
Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.联合治疗在高血压治疗中的作用:聚焦缬沙坦联合氨氯地平
Adv Ther. 2008 Apr;25(4):300-20. doi: 10.1007/s12325-008-0042-x.
4
Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.缬沙坦与氢氯噻嗪两种固定剂量复方制剂与缬沙坦单药治疗对2或3期收缩期高血压患者的降压疗效及耐受性比较:一项为期8周的随机、双盲、平行组试验
Clin Ther. 2005 Jul;27(7):1013-21. doi: 10.1016/j.clinthera.2005.07.010.
5
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.缬沙坦联合氢氯噻嗪与氨氯地平单药治疗对伴有其他心血管危险因素的高血压患者的疗效及耐受性比较:VAST研究
Clin Ther. 2005 May;27(5):578-87. doi: 10.1016/j.clinthera.2005.05.006.
6
Sexual activity in hypertensive men.高血压男性的性行为
J Hum Hypertens. 2003 Aug;17(8):515-21. doi: 10.1038/sj.jhh.1001580.
7
Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.力滴定缬沙坦/氢氯噻嗪与氨氯地平/氢氯噻嗪对2期高血压患者动态血压的影响:EVALUATE研究
Blood Press Monit. 2009 Jun;14(3):112-20. doi: 10.1097/MBP.0b013e32832a9da7.
8
Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?肾素-血管紧张素系统抑制对靶器官保护的作用:我们能否做得更好?
Clin Ther. 2007 Sep;29(9):1803-24. doi: 10.1016/j.clinthera.2007.09.019.
9
[High dose sartan plus diuretic. More power in hypertension and its sequelae].[高剂量沙坦类药物加利尿剂。治疗高血压及其后遗症更有效]
MMW Fortschr Med. 2003 Mar 13;145(11):59.
10
Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.缬沙坦/氢氯噻嗪联合治疗在重度高血压初始治疗中的疗效及耐受性
Curr Med Res Opin. 2008 Aug;24(8):2303-11. doi: 10.1185/03007990802271946. Epub 2008 Jun 28.

引用本文的文献

1
Combining angiotensin receptor blockers with chlorthalidone or hydrochlorothiazide - which is the better alternative? A meta-analysis.联合应用血管紧张素受体阻滞剂与氯噻酮或氢氯噻嗪——哪一种是更好的选择?一项荟萃分析。
Syst Rev. 2020 Aug 24;9(1):195. doi: 10.1186/s13643-020-01457-9.
2
Renal secretion of hydrochlorothiazide involves organic anion transporter 1/3, organic cation transporter 2, and multidrug and toxin extrusion protein 2-K.氢氯噻嗪的肾分泌涉及有机阴离子转运蛋白 1/3、有机阳离子转运蛋白 2 和多药和毒素外排蛋白 2-K。
Am J Physiol Renal Physiol. 2019 Oct 1;317(4):F805-F814. doi: 10.1152/ajprenal.00141.2019. Epub 2019 Jul 19.
3
Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control.
基于奥美沙坦的三联组合疗法:一种改善血压控制的个性化治疗方法。
High Blood Press Cardiovasc Prev. 2017 Sep;24(3):255-263. doi: 10.1007/s40292-017-0217-0. Epub 2017 Jun 12.
4
Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program.缬沙坦对高血压和总体心血管风险的真实世界疗效:一项转化研究计划的综述与启示
Vasc Health Risk Manag. 2011;7:209-35. doi: 10.2147/VHRM.S9434. Epub 2011 Mar 31.
5
Compliance with the treatment of hypertension: the potential of combination therapy.高血压治疗的依从性:联合治疗的潜力。
J Clin Hypertens (Greenwich). 2010 Jan;12(1):40-6. doi: 10.1111/j.1751-7176.2009.00200.x.
6
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial.厄贝沙坦/氢氯噻嗪固定复方制剂治疗高血压女性的疗效与安全性:包容性试验
J Womens Health (Larchmt). 2008 Jul-Aug;17(6):931-8. doi: 10.1089/jwh.2008.0499.
7
Predictors of blood pressure response to angiotensin receptor blocker/diuretic combination therapy: a secondary analysis of the irbesartan/hydrochlorothiazide blood pressure reductions in diverse patient populations (INCLUSIVE) study.血管紧张素受体阻滞剂/利尿剂联合治疗血压反应的预测因素:厄贝沙坦/氢氯噻嗪在不同患者群体中降低血压情况的二次分析(包容性)研究
J Clin Hypertens (Greenwich). 2008 Jan;10(1):27-33. doi: 10.1111/j.1524-6175.2007.07195.x.
8
The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk.厄贝沙坦/氢氯噻嗪固定剂量复方制剂初始用于有和无高心血管风险的高血压患者的疗效和安全性。
J Clin Hypertens (Greenwich). 2007 Dec;9(12 Suppl 5):23-30. doi: 10.1111/j.1524-6175.2007.07805.x.
9
The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.血管紧张素II 1型受体拮抗剂在老年高血压患者中的作用。
Drugs Aging. 2006;23(2):131-55. doi: 10.2165/00002512-200623020-00004.
10
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.厄贝沙坦/氢氯噻嗪低剂量和高剂量固定复方制剂用于单药治疗后收缩压仍未控制的患者的疗效与安全性:INCLUSIVE试验
J Clin Hypertens (Greenwich). 2005 Oct;7(10):578-86. doi: 10.1111/j.1524-6175.2004.04720.x.